Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Burning Rock Biotech Limited before investing.

In this article, we go over a few key elements for understanding Burning Rock Biotech Limited’s stock price such as:

• Burning Rock Biotech Limited’s current stock price and volume
• Why Burning Rock Biotech Limited’s stock price changed recently
• Upgrades and downgrades for BNR from analysts
• BNR’s stock price momentum as measured by its relative strength

About Burning Rock Biotech Limited (BNR)

Before we jump into Burning Rock Biotech Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. The company also provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients, as well as Magnis BR-customized version of its principal products. In addition, it offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Want to learn more about Burning Rock Biotech Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Burning Rock Biotech Limited.

Burning Rock Biotech Limited’s Stock Price as of Market Close

As of March 25, 2025, 3:59 PM, CST, Burning Rock Biotech Limited’s stock price was $4.820.

Burning Rock Biotech Limited is down 12.36% from its previous closing price of $5.500.

During the last market session, Burning Rock Biotech Limited’s stock traded between $4.600 and $5.680. Currently, there are approximately 1.47 million shares outstanding for Burning Rock Biotech Limited.

Burning Rock Biotech Limited’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Burning Rock Biotech Limited Stock Price History

Burning Rock Biotech Limited’s (BNR) price is currently down 23.61% so far this month.

During the month of March, Burning Rock Biotech Limited’s stock price has reached a high of $6.330 and a low of $0.000.

Over the last year, Burning Rock Biotech Limited has hit prices as high as $8.990 and as low as $2.620. Year to date, Burning Rock Biotech Limited’s stock is down 28.59%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Burning Rock Biotech Limited Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 24, 2025, there were analysts who downgraded Burning Rock Biotech Limited’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Burning Rock Biotech Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Burning Rock Biotech Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Burning Rock Biotech Limited’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Burning Rock Biotech Limited (BNR) by visiting AAII Stock Evaluator.

Relative Price Strength of Burning Rock Biotech Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 24, 2025, Burning Rock Biotech Limited has a weighted four-quarter relative price strength of -3.04%, which translates to a Momentum Score of 43 and is considered to be Average.

Want to learn more about how Burning Rock Biotech Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Burning Rock Biotech Limited Stock Price: Bottom Line

As of March 25, 2025, Burning Rock Biotech Limited’s stock price is $4.820, which is down 12.36% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Burning Rock Biotech Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.